PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11216854-5	2001	In this study, the protein synthesis inhibitor cycloheximide was used as a tool to understand Pgp gene expression and regulation in animal tissues.	Cycloheximide	47-60	ATP binding cassette subfamily B member 1	Homo sapiens	94-97	
11216854-0	2001	Induction of P-glycoprotein mRNA transcripts by cycloheximide in animal tissues: evidence that class I Pgp is transcriptionally regulated whereas class II Pgp is post-transcriptionally regulated.	Cycloheximide	48-61	ATP binding cassette subfamily B member 1	Homo sapiens	13-27	
11216854-7	2001	The results showed that cycloheximide significantly induced class II Pgp expression in all tissues examined.	Cycloheximide	24-37	ATP binding cassette subfamily B member 1	Homo sapiens	69-72	
11216854-0	2001	Induction of P-glycoprotein mRNA transcripts by cycloheximide in animal tissues: evidence that class I Pgp is transcriptionally regulated whereas class II Pgp is post-transcriptionally regulated.	Cycloheximide	48-61	ATP binding cassette subfamily B member 1	Homo sapiens	103-106	
11216854-9	2001	In contrast, the relatively modest increase in class I Pgp expression by cycloheximide was found to be mainly due to increased transcriptional activity.	Cycloheximide	73-86	ATP binding cassette subfamily B member 1	Homo sapiens	55-58	
11216854-10	2001	On the other hand, cycloheximide induced class III Pgp expression in some tissues while caused decay of class III Pgp mRNA in other tissues.	Cycloheximide	19-32	ATP binding cassette subfamily B member 1	Homo sapiens	51-54	
11216854-10	2001	On the other hand, cycloheximide induced class III Pgp expression in some tissues while caused decay of class III Pgp mRNA in other tissues.	Cycloheximide	19-32	ATP binding cassette subfamily B member 1	Homo sapiens	114-117	
11216854-11	2001	The transcriptional and post-transcriptional mechanisms exerted by cycloheximide on Pgp genes are discussed.	Cycloheximide	67-80	ATP binding cassette subfamily B member 1	Homo sapiens	84-87	
10026303-3	1999	After treatment of MCF-7 cells with cycloheximide (CHX), MDR1 mRNA reached detectable levels, suggesting that MDR1 mRNA expression might be controlled by a labile negative regulatory protein(s) in MCF-7 cells.	Cycloheximide	36-49	ATP binding cassette subfamily B member 1	Homo sapiens	57-61	
10441477-5	1999	The MDR1 mRNA half-life was prolonged to >20 h upon treatment with the protein synthesis inhibitor cycloheximide.	Cycloheximide	102-115	ATP binding cassette subfamily B member 1	Homo sapiens	4-8	
10026303-3	1999	After treatment of MCF-7 cells with cycloheximide (CHX), MDR1 mRNA reached detectable levels, suggesting that MDR1 mRNA expression might be controlled by a labile negative regulatory protein(s) in MCF-7 cells.	Cycloheximide	36-49	ATP binding cassette subfamily B member 1	Homo sapiens	110-114	
10026303-3	1999	After treatment of MCF-7 cells with cycloheximide (CHX), MDR1 mRNA reached detectable levels, suggesting that MDR1 mRNA expression might be controlled by a labile negative regulatory protein(s) in MCF-7 cells.	Cycloheximide	51-54	ATP binding cassette subfamily B member 1	Homo sapiens	57-61	
10026303-3	1999	After treatment of MCF-7 cells with cycloheximide (CHX), MDR1 mRNA reached detectable levels, suggesting that MDR1 mRNA expression might be controlled by a labile negative regulatory protein(s) in MCF-7 cells.	Cycloheximide	51-54	ATP binding cassette subfamily B member 1	Homo sapiens	110-114	
7476894-7	1995	The increased expression was suppressed by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole, an RNA synthesis inhibitor, whereas the protein synthesis inhibitor cycloheximide enhanced the expression several-fold, suggesting that induction of mdr1 by these analogues is regulated at both the transcriptional and post-transcriptional levels.	Cycloheximide	161-174	ATP binding cassette subfamily B member 1	Homo sapiens	242-246